AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

AIM ImmunoTech highlighted an exploratory Dutch Named Patient Program analysis in which 39 pancreatic-cancer patients with NLR below 4.5 had median overall survival of 34.8 months from the start of FOLFIRINOX after receiving Ampligen maintenance therapy. The company stressed that differences in patient selection, disease stage and survival measurement preclude direct comparisons with other studies and that randomized trials are needed. Topline data from the Phase 2 DURIPANC trial of Ampligen plus AstraZeneca's durvalumab are expected in Q1 2027, with overall-survival analysis beginning in Q3 2027 and potentially informing a pivotal Phase 3 program.

Analysis

This is promotional, non-randomized evidence rather than a valuation-changing clinical update. The apparent survival signal is highly vulnerable to selection bias: radiographic stability after frontline therapy and low NLR both identify patients with inherently better prognosis, while survival is measured from an earlier treatment start. Without a contemporaneous control and prespecified biomarker interaction, the data do not establish incremental efficacy attributable to Ampligen.

For AIM, the investable catalyst is narrow and binary: Q1 2027 clinical-benefit-rate data can support a biomarker-enriched development narrative, but it is not an approval-grade endpoint. The more consequential read-through begins with durability, PFS, safety, and eventual OS maturation in 2027; a favorable CBR without separation in time-to-event endpoints would likely create only transient financing-window strength. Funding runway, dilution terms, enrollment completion, and the exact analysis population matter more over the next 3-6 months than this communication.

AZN has effectively no economic sensitivity. Durvalumab supply in a small investigator-sponsored Phase 2 does not move Imfinzi revenue or alter AZN's pancreatic-cancer valuation; any strategic read-through requires credible randomized evidence. Contrarian view: microcap investors may chase the headline's cross-trial survival framing, but sophisticated buyers should discount it until randomized data demonstrate that low NLR is predictive rather than merely prognostic.

Key Decisions for Investors

• No core long in AIM on this release; treat any near-term liquidity-driven rally as an opportunity to reduce or avoid exposure unless the company discloses enrollment completion, cash runway through the Q1 2027 readout, and a prespecified biomarker analysis plan.
• For biotech-event capital, place AIM on a Q1 2027 catalyst watchlist rather than initiating now. Consider a small defined-risk long only after confirmation of adequate funding and trial execution; size for a binary outcome and assume substantial downside if 24-week CBR misses or safety limits combination dosing.
• Use a post-data decision rule: a durable CBR/PFS signal with a credible low-NLR interaction supports a tactical long into OS updates; positive CBR without PFS durability, or no biomarker interaction, falsifies the differentiated-development thesis and argues for exit.
• Do not express this thesis through AZN. Its exposure is immaterial; a better healthcare pair, if AIM becomes crowded ahead of data, is short AIM versus a diversified oncology-biotech ETF such as XBI, with the spread risk capped by a pre-specified maximum loss due to AIM's high short-squeeze and financing volatility.